Artificial nerve grafts are needed to reconstruct massive defects in the peripheral nervous system when autologous nerve grafts are not available in sufficient amounts. Nerve grafts containing Schwann cells display a suitable substrate for long-distance regeneration. We present here a comprehensive analysis of the in vivo effects of different isoforms of fibroblast growth factor-2 (FGF-2) on peripheral nerve regeneration across long gaps. FGF-2 isoforms were provided by grafted, genetically modified Schwann cells over-expressing 18-kDa-FGF-2 and 21-/23-kDa-FGF-2, respectively. Functional tests evaluated motor and sensory recovery. Additionally, morphometrical analyses of regenerated nerves were performed 3 and 6 months after grafting. Distinct regeneration promoting effects of the different FGF-2 isoforms were found. 18-kDa-FGF-2 mediated inhibitory effects on the grade of myelination of regenerating axons, whereas 21-/23-kDa-FGF-2 mediated early recovery of sensory functions and stimulation of longdistance myelination of regenerating axons. The results contribute to the development of new therapeutic strategies in peripheral nerve repair. D
Introduction
A complete nerve transection is the most severe peripheral nerve injury and is primarily seen in obstetrical and traumatic brachial plexus lesions, but can also be seen in advanced extremity injuries. Depending on the distance between the nerve stumps, treatment typically consists of either direct end-to-end anastomosis of the cut nerve ends or the use of an autologous nerve graft (Schmidt and Leach, 2003) . The availability of autologous nerve transplants is especially limited when a large amount of grafting material is needed as in massive peripheral nerve lesions, because it requires sacrifices of healthy nerves (Lundborg, 2004) . There are experimental and clinical approaches to use synthetic guidance channels in peripheral nerve regeneration (Nakamura et al., 2004) . However, the golden standard is still transplantation of autologous nerve grafts as they provide a scaffold which contains Schwann cell basal laminae and growth factor constituting optimal growth substrate and environment for regrowing axons (Ansselin et al., 1997; Bunge, 1993; Lundborg, 2004) . For development of an optimal artificial nerve graft as alternative to autologous ones, it is of high interest to combine synthetic nerve guides with preferentially autologous Schwann cell transplants and the respective biologically active molecules.
Artificial nerve grafts filled with physiological Schwann cells from neonatal (Hadlock et al., 2000; Mosahebi et al., 2002) and adult rats (Ansselin et al., 1997; Guenard et al., 1992 ) stimulated nerve fiber regeneration. Enhanced morphological peripheral nerve regeneration has also been seen after treatment with nerve growth factor (NGF) either slowly released from synthetic nerve guides (Fine et al., 2002) or from NGF-containing polymeric microspheres within synthetic nerve guides (Fine et al., 2002; Xu et al., 2003) or to a even better extent after treatment with glial-derived neurotrophic factor also slowly released from synthetic nerve guides (Fine et al., 2002) . Furthermore, it has been shown previously that entrapment of the low molecular weight (18-kDa) isoform of fibroblast growth factor-2 (FGF-2) in synthetic nerve guidance channels is able to enhance growth of myelinated and unmyelinated axons across long gaps significantly (Aebischer et al., 1989) . With regard to the low and high molecular weight FGF-2 isoforms, it has been shown that the isoforms are differentially regulated following peripheral nerve injury, indicating differential physiological functions during peripheral nerve regeneration (for review, see: Grothe and Nikkhah, 2001 
